Elucent Medical secures Series C funding for oncologic surgery innovation

Elucent Medical announced the successful closure of its $42.5 million Series C funding round. The proceeds will further propel the development and commercialization of its groundbreaking EnVisio® and SmartClip® technologies for tissue sparing oncologic surgery.

The financing was led by Vensana Capital and RC Capital with participation from existing investors. This investment validates the growing interest in Elucent’s transformative approach to enhancing precision and efficacy in cancer surgery.

Elucent’s flagship technologies, EnVisio® and SmartClip®, offer precision In-Site Spatial Intelligence during oncologic procedures. EnVisio® leverages proprietary technology that converts existing surgical tools to smart navigated instruments that can be tracked in real-time and guided with millimeter precision. EnVisio is currently optimized to guide the surgical treatment of breast cancer, while adoption of the technology has expanded to address other soft tissue oncology surgeries. In addition, Elucent is currently developing products to assist surgeons in their pursuit of margin negative resections in lung and other soft tissue clinical applications, and these products also integrate with existing tools and minimally invasive solutions, including video and robotic-assisted medical technologies.

“We are proud to have secured this substantial funding, which will advance our mission to radically change the way surgeons mark and locate their intended target for removal by turning their existing surgical instruments into intelligent tracking devices that elevate the standard of care in soft tissue oncologic procedures,” says Jason Pesterfield, President and CEO of Elucent Medical. “With the support of our investors, we are poised to accelerate the commercialization of our EnVisio® and SmartClip® technologies, empowering healthcare providers with innovative tools to improve patient outcomes.”

New board members Greg Banker and Kirk Nielsen of Vensana Capital and Scott Steever of RC Capital added, “Elucent has developed a best-in-class technology platform that integrates with existing surgical tools and workflows while providing surgeons the real-time information they need to confidently locate and optimally resect tumors. We are excited to partner with the company to support their efforts to establish themselves as the market leader in breast navigation and to complete the development and launch of products in lung and other soft-tissue applications.”
MB Bureau